World Sleep Industry ENCYCLOPEDIA

Sodium Oxybate

2.1.1

Drug identity, action, and limits of the indication

Sodium oxybate is the sodium salt of gamma-hydroxybutyrate, or GHB, and a rapidly acting central nervous system depressant. GHB is an endogenous compound and a metabolite of gamma-aminobutyric acid. The full mechanism by which sodium oxybate treats narcolepsy is unknown, although GABA-B-related pathways may contribute. In the United States it is a Schedule III prescription drug with a boxed warning; the fact that GHB occurs naturally in the body does not make the medicine harmless or an ordinary sleep aid.

Current US labels for immediate- and extended-release sodium oxybate indicate treatment of cataplexy or excessive daytime sleepiness in people seven years of age and older with narcolepsy. It does not cure narcolepsy and is not a general treatment for insomnia, ordinary sleep deprivation, nonspecific fatigue, or nonmedical sedation. Lower-sodium mixed oxybate salts have a different composition and labeling, so indications, sodium content, and instructions cannot be transferred merely because each product contains an oxybate.

Evidence, symptom targets, and continuing risk

A professional guideline strongly recommends sodium oxybate for adults with narcolepsy and conditionally suggests it for pediatric narcolepsy. Randomized trials and systematic reviews show average reductions in cataplexy, lower subjective sleepiness, and longer objectively measured wakefulness; some studies also report more consolidated nighttime sleep. These are group effects in selected patients. Individual benefit and tolerability vary, so the evidence does not promise symptom elimination or safety in daily activities.

Cataplexy is typically a brief, emotion-triggered loss of muscle tone with preserved awareness and must be distinguished from seizures, syncope, falls, and other episodes of weakness. Excessive daytime sleepiness also requires assessment for insufficient sleep, medicines and substances, sleep-disordered breathing, and other illness. Sleepiness, cataplexy, and unintended sleep may persist during treatment, making continued tracking of function, attacks, nighttime sleep, and near misses essential. A marked return of cataplexy after stopping may reflect recurrence of the underlying disorder and still requires clinical distinction from withdrawal or another problem.

Formulation differences, the nighttime process, and error prevention

Sodium oxybate comes in formulations with different release profiles and packaging. Some immediate-release liquids divide the total nightly amount between bedtime and a second dose several hours later, whereas an extended-release suspension is used once nightly according to its label. Preparation containers, water volume, food interval, second-dose procedures, and storage windows differ. A switch belongs under prescriber direction using the exact product labeling; patients should not combine a nightly amount into one dose, split it into extra doses, or convert concentrations with kitchen measures or old containers.

The medicine is generally taken after the required fasting interval, while already in bed, followed by lying down immediately because sleep may begin abruptly without a clear warning of drowsiness. For divided-dose products, both portions are prepared as directed before bedtime and the second container is kept in a secure place. If a dose is missed, spilled, vomited, or possibly taken already, a person should not add more or take two portions together, but follow that product's instructions and contact a professional. The household plan must also prevent access by children, visitors, or housemates.

CNS depression, respiratory danger, and prohibited combinations

Sodium oxybate can cause obtundation, profound sedation, and respiratory depression. Alcohol and sedative-hypnotic drugs are contraindicated under current US labels. Opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating antiseizure medicines, general anesthetics, muscle relaxants, and other CNS depressants can further increase hypotension, syncope, profound sedation, respiratory depression, and death. Every prescriber must be told about sodium oxybate before surgery, emergency pain treatment, or the addition of any sedating medicine.

The medicine may impair respiratory drive and has been associated with central apneas and clinically important oxygen desaturation. People with OSA, lung disease, obesity, or another respiratory risk need specific evaluation and follow-up; an average finding from one study cannot establish safety for every individual. Succinic semialdehyde dehydrogenase deficiency is also a contraindication. Difficulty awakening, slow or shallow breathing, pauses in breathing, blue lips, collapse, or severe confusion after a dose requires emergency help, not an attempt to let the person sleep it off.

Next-day safety, falls, parasomnias, and common adverse effects

Current US labeling prohibits driving, operating machinery, flying, or other hazardous activities requiring full alertness and coordination for at least six hours after a dose, and treatment should not proceed as though safe until its effects are known. That minimum interval is not automatic clearance to drive. Continued morning sleepiness, dizziness, slowed responses, abnormal vision, or unstable attention means hazardous activity should remain off limits and the clinical team should be contacted. Abrupt sleep has occurred while standing or rising from bed and has caused falls and injuries requiring hospitalization.

Common adverse effects include nausea, dizziness, vomiting, somnolence, enuresis, and tremor. Diarrhea, sweating, impaired attention, a drunken feeling, and changes in weight or appetite can also occur. Sleepwalking and other parasomnias may involve wandering and injury and require full evaluation, with hazards such as stairs, fire, sharp objects, and exits addressed. More confusion, vomiting, bedwetting, or unusual behavior after an increase is not necessarily a harmless adjustment phase and should not prompt self-directed persistence or another increase.

Mental health, sodium burden, and special populations

Depression and suicidal thoughts or behavior can emerge during treatment. Confusion, anxiety, hallucinations, paranoia, psychosis, agitation, and aggression have also been reported. People with a history of depression, a suicide attempt, or another psychiatric illness need particular monitoring. New self-harm thoughts, marked behavioral or personality change, or loss of reality testing requires immediate help. Nighttime behavior, memory gaps, and mood changes observed by a partner or caregiver should be part of follow-up.

Sodium oxybate products can add a substantial sodium burden. People with heart failure, hypertension, or kidney impairment should include medicine-derived sodium in the daily total rather than count food alone. Divalproex sodium can increase GHB exposure and worsen performance on some attention and working-memory tests, requiring prescriber adjustment and monitoring; hepatic impairment also needs a specific regimen. Human pregnancy data are inadequate, and GHB enters human milk. Preconception, pregnancy, breastfeeding, older age, and pediatric use each need individualized review, with weight and available product strengths additionally relevant for children.

Restricted distribution, misuse, dependence, overdose, and review

In the United States, sodium oxybate is available only through the REMS restricted-distribution program for the specific product because of CNS depression, abuse, and misuse risks. Prescribers, pharmacies, and patients must meet safe-use conditions. Rapid sedation, amnesia, and reinforcing effects make self-directed increases in dose or frequency, early refills, multiple prescribers, sharing, or sale serious warning signs. Frequent high-dose illicit GHB use can cause severe dependence and withdrawal that includes insomnia, anxiety, tremor, sweating, tachycardia, hallucinations, and delirium; prescribed treatment likewise should not be stopped abruptly without clinical direction.

In overdose, consciousness can fluctuate rapidly between agitated confusion and coma, with ataxia, vomiting, incontinence, myoclonus, seizures, apnea, or acidosis. Emergency and poison-control help is required, including disclosure of possible alcohol or other drug exposure. Do not induce vomiting; clinical care centers on airway and breathing support with continued monitoring. The medicine must be kept tightly closed, child-resistant, and securely stored according to the exact label and never shared. Long-term review should examine meaningful benefit, breathing, mental state, parasomnias, sodium burden, signs of misuse, and whether the original diagnosis remains valid.